Hesheng Wang1, Reza Farjam2, Mary Feng2, Hero Hussain3, Randall K Ten Haken2, Theodore S Lawrence2, Yue Cao4. 1. Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan. Electronic address: hesheng@umich.edu. 2. Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan. 3. Department of Radiology, University of Michigan, Ann Arbor, Michigan. 4. Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan; Department of Radiology, University of Michigan, Ann Arbor, Michigan; Department of Biomedical Engineering, University of Michigan, Ann Arbor, Michigan.
Abstract
PURPOSE: To assess whether an increase in a subvolume of intrahepatic tumor with elevated arterial perfusion during radiation therapy (RT) predicts tumor progression after RT. METHODS AND MATERIALS: Twenty patients with unresectable intrahepatic cancers undergoing RT were enrolled in a prospective, institutional review board-approved study. Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) was performed before RT (pre-RT), after delivering ∼60% of the planned dose (mid-RT) and 1 month after completion of RT to quantify hepatic arterial perfusion. The arterial perfusions of the tumors at pre-RT were clustered into low-normal and elevated perfusion by a fuzzy clustering-based method, and the tumor subvolumes with elevated arterial perfusion were extracted from the hepatic arterial perfusion images. The percentage changes in the tumor subvolumes and means of arterial perfusion over the tumors from pre-RT to mid-RT were evaluated for predicting tumor progression post-RT. RESULTS: Of the 24 tumors, 6 tumors in 5 patients progressed 5 to 21 months after RT completion. Neither tumor volumes nor means of tumor arterial perfusion at pre-RT were predictive of treatment outcome. The mean arterial perfusion over the tumors increased significantly at mid-RT in progressive tumors compared with the responsive tumors (P=.006). From pre-RT to mid-RT, the responsive tumors had a decrease in the tumor subvolumes with elevated arterial perfusion (median, -14%; range, -75% to 65%), whereas the progressive tumors had an increase of the subvolumes (median, 57%; range, -7% to 165%) (P=.003). Receiver operating characteristic analysis of the percentage change in the subvolume for predicting tumor progression post-RT had an area under the curve of 0.90. CONCLUSION: The increase in the subvolume of the intrahepatic tumor with elevated arterial perfusion during RT has the potential to be a predictor for tumor progression post-RT. The tumor subvolume could be a radiation boost candidate for response-driven adaptive RT. Published by Elsevier Inc.
PURPOSE: To assess whether an increase in a subvolume of intrahepatic tumor with elevated arterial perfusion during radiation therapy (RT) predicts tumor progression after RT. METHODS AND MATERIALS: Twenty patients with unresectable intrahepatic cancers undergoing RT were enrolled in a prospective, institutional review board-approved study. Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) was performed before RT (pre-RT), after delivering ∼60% of the planned dose (mid-RT) and 1 month after completion of RT to quantify hepatic arterial perfusion. The arterial perfusions of the tumors at pre-RT were clustered into low-normal and elevated perfusion by a fuzzy clustering-based method, and the tumor subvolumes with elevated arterial perfusion were extracted from the hepatic arterial perfusion images. The percentage changes in the tumor subvolumes and means of arterial perfusion over the tumors from pre-RT to mid-RT were evaluated for predicting tumor progression post-RT. RESULTS: Of the 24 tumors, 6 tumors in 5 patients progressed 5 to 21 months after RT completion. Neither tumor volumes nor means of tumor arterial perfusion at pre-RT were predictive of treatment outcome. The mean arterial perfusion over the tumors increased significantly at mid-RT in progressive tumors compared with the responsive tumors (P=.006). From pre-RT to mid-RT, the responsive tumors had a decrease in the tumor subvolumes with elevated arterial perfusion (median, -14%; range, -75% to 65%), whereas the progressive tumors had an increase of the subvolumes (median, 57%; range, -7% to 165%) (P=.003). Receiver operating characteristic analysis of the percentage change in the subvolume for predicting tumor progression post-RT had an area under the curve of 0.90. CONCLUSION: The increase in the subvolume of the intrahepatic tumor with elevated arterial perfusion during RT has the potential to be a predictor for tumor progression post-RT. The tumor subvolume could be a radiation boost candidate for response-driven adaptive RT. Published by Elsevier Inc.
Authors: C C Ling; J Humm; S Larson; H Amols; Z Fuks; S Leibel; J A Koutcher Journal: Int J Radiat Oncol Biol Phys Date: 2000-06-01 Impact factor: 7.038
Authors: R Materne; B E Van Beers; A M Smith; I Leconte; J Jamart; J P Dehoux; A Keyeux; Y Horsmans Journal: Clin Sci (Lond) Date: 2000-12 Impact factor: 6.124
Authors: Piet Dirix; Vincent Vandecaveye; Frederik De Keyzer; Sigrid Stroobants; Robert Hermans; Sandra Nuyts Journal: J Nucl Med Date: 2009-06-12 Impact factor: 10.057
Authors: Reza Farjam; Christina I Tsien; Felix Y Feng; Diana Gomez-Hassan; James A Hayman; Theodore S Lawrence; Yue Cao Journal: Int J Radiat Oncol Biol Phys Date: 2012-12-17 Impact factor: 7.038
Authors: Abby B Siegel; Emil I Cohen; Allyson Ocean; Deborah Lehrer; Alec Goldenberg; Jennifer J Knox; Helen Chen; Sean Clark-Garvey; Alan Weinberg; John Mandeli; Paul Christos; Madhu Mazumdar; Elizabeta Popa; Robert S Brown; Shahin Rafii; Jonathan D Schwartz Journal: J Clin Oncol Date: 2008-06-20 Impact factor: 44.544
Authors: Hugo J W L Aerts; Geert Bosmans; Angela A W van Baardwijk; Andre L A J Dekker; Michel C Oellers; Philippe Lambin; Dirk De Ruysscher Journal: Int J Radiat Oncol Biol Phys Date: 2008-01-30 Impact factor: 7.038
Authors: Andrew X Zhu; Dushyant V Sahani; Dan G Duda; Emmanuelle di Tomaso; Marek Ancukiewicz; Onofrio A Catalano; Vivek Sindhwani; Lawrence S Blaszkowsky; Sam S Yoon; Johanna Lahdenranta; Pankaj Bhargava; Jeffrey Meyerhardt; Jeffrey W Clark; Eunice L Kwak; Aram F Hezel; Rebecca Miksad; Thomas A Abrams; Peter C Enzinger; Charles S Fuchs; David P Ryan; Rakesh K Jain Journal: J Clin Oncol Date: 2009-05-26 Impact factor: 44.544
Authors: Mary Feng; Krithika Suresh; Matthew J Schipper; Latifa Bazzi; Edgar Ben-Josef; Martha M Matuszak; Neehar D Parikh; Theodore H Welling; Daniel Normolle; Randall K Ten Haken; Theodore S Lawrence Journal: JAMA Oncol Date: 2018-01-01 Impact factor: 31.777
Authors: Mingquan Lin; Jacob F Wynne; Boran Zhou; Tonghe Wang; Yang Lei; Walter J Curran; Tian Liu; Xiaofeng Yang Journal: J Appl Clin Med Phys Date: 2021-06-24 Impact factor: 2.102